Skip to main content

Advertisement

SpringerLink
Log in

Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

The purpose of the present study was to evaluate the long-term incidence and timing of reactivation in patients with type 3 neovascularization who were treated with three monthly anti-vascular endothelial growth factor (VEGF) injections.

Methods

A total of 179 patients (179 eyes) diagnosed with type 3 neovascularization with dry macula after three monthly anti-VEGF loading injections were included in this retrospective study. After the initial treatment, patients were followed up without further injection until the first reactivation. The incidence and timing of the first reactivation after the initial treatment were recorded, and factors predictive of early reactivation (≤ 6 months after the third anti-VEGF injection) were investigated.

Results

During a mean follow-up of 37.5 ± 18.8 months, the first reactivation was noted in 145 patients (81.0%) at a mean of 6.6 ± 4.1 months after the third injection. In 94 eyes (64.8%), reactivation was noted 2–6 months after the third injection, while in 37 eyes (25.5%) it was noted 7–12 months after the third injection. In the remaining 14 eyes (9.7%), the reactivation was noted after this period. The incidence of early reactivation was higher in women (P = 0.014) and patients with thicker choroid (P = 0.026).

Conclusions

In patients with type 3 neovascularization, almost all reactivation was noted within 15 months of the third anti-VEGF injection, suggesting the need for close follow-up and detailed examination during this period. Female patients with thick choroid should be monitored more frequently during this early period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Congdon N, O’Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122:477–485

    Article  PubMed  Google Scholar 

  2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431

    Article  CAS  PubMed  Google Scholar 

  3. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548

    Article  PubMed  Google Scholar 

  4. Fauser S, Muether PS (2016) Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol 100:1494–1498

    Article  PubMed  Google Scholar 

  5. Okada M, Kandasamy R, Chong EW, McGuiness M, Guymer RH (2018) The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis. Am J Ophthalmol 192:184–197

    Article  PubMed  Google Scholar 

  6. Hatz K, Prunte C (2016) Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol 100:1341–1345

    Article  PubMed  Google Scholar 

  7. Smiddy WE (2009) Economic implications of current age-related macular degeneration treatments. Ophthalmology 116:481–487

    Article  PubMed  Google Scholar 

  8. Senra H, Ali Z, Balaskas K, Aslam T (2016) Psychological impact of anti-VEGF treatments for wet macular degeneration-a review. Graefes Arch Clin Exp Ophthalmol 254:1873–1880

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122:2303–2310

    Article  PubMed  Google Scholar 

  10. Kim JH, Chang YS, Lee DW, Kim CG, Kim JW (2017) Incidence and timing of the first recurrence in neovascular age-related macular degeneration: comparison between ranibizumab and aflibercept. J Ocul Pharmacol Ther 33:445–451

    Article  CAS  PubMed  Google Scholar 

  11. Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2017) Recurrence in patients with type 3 neovascularization (retinal angiomatous proliferation) after intravitreal ranibizumab. Retina 37:1508–1515

    Article  CAS  PubMed  Google Scholar 

  12. Freund KB, Ho IV, Barbazetto IA, Koizumi H, Laud K, Ferrara D, Matsumoto Y, Sorenson JA, Yannuzzi L (2008) Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 28:201–211

    Article  PubMed  Google Scholar 

  13. Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, Freund KB, Sorenson J, Orlock D, Borodoker N (2001) Retinal angiomatous proliferation in age-related macular degeneration. Retina 21:416–434

    Article  CAS  PubMed  Google Scholar 

  14. Nagiel A, Sarraf D, Sadda SR, Spaide RF, Jung JJ, Bhavsar KV, Ameri H, Querques G, Freund KB (2015) Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography. Retina 35:638–647

    Article  PubMed  Google Scholar 

  15. Su D, Lin S, Phasukkijwatana N, Chen X, Tan A, Freund KB, Sarraf D (2016) An updated staging system of type 3 neovascularization using spectral domain optical coherence tomography. Retina 36(Suppl 1):S40–S49

    Article  PubMed  Google Scholar 

  16. Xu L, Mrejen S, Jung JJ, Gallego-Pinazo R, Thompson D, Marsiglia M, Freund KB (2015) Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Retina 35:176–186

    Article  CAS  PubMed  Google Scholar 

  17. Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF (2014) Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121:150–161

    Article  PubMed  Google Scholar 

  18. Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M (2014) Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology 121:1079–1091

    Article  PubMed  Google Scholar 

  19. Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG (2016) Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology 123:609–616

    Article  PubMed  Google Scholar 

  20. Mrejen S, Jung JJ, Chen C, Patel SN, Gallego-Pinazo R, Yannuzzi N, Xu L, Marsiglia M, Boddu S, Freund KB (2015) Long-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degeneration. J Clin Med 4:1380–1402

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Abdelfattah NS, Zhang H, Boyer DS, Sadda SR (2016) Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy. Retina 36:1843–1850

    Article  CAS  PubMed  Google Scholar 

  22. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583

    Article  CAS  PubMed  Google Scholar 

  23. Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, Staurenghi G, Wittrup-Jensen K, Altemark A, Nilsson J, Kim K, Sivaprasad S (2016) Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol 100:1623–1628

    Article  PubMed  Google Scholar 

  24. Kim YK, Park SJ, Woo SJ, Park KH (2016) Choroidal thickness change after intravitreal anti-vascular endothelial growth factor treatment in retinal angiomatous proliferation and its recurrence. Retina 36:1516–1526

    Article  CAS  PubMed  Google Scholar 

  25. Nickla DL, Wallman J (2010) The multifunctional choroid. Prog Retin Eye Res 29:144–168

    Article  PubMed  Google Scholar 

  26. Barthelmes D, Nguyen V, Walton R, Gillies MC, Daien V (2018) A pharmacoepidemiologic study of ranibizumab and aflibercept use 2013-2016. The Fight Retinal Blindness! Project. Graefes Arch Clin Exp Ophthalmol 256(10):1839–1846. https://doi.org/10.1007/s00417-018-4061-2

    Article  CAS  PubMed  Google Scholar 

  27. Cho HJ, Hwang HJ, Kim HS, Han JI, Lee DW, Kim JW (2017) Intravitreal aflibercept and ranibizumab injections for type 3 neovascularization. Retina 38(11):2150–2158. https://doi.org/10.1097/IAE.0000000000001862

    Article  CAS  Google Scholar 

  28. Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A (2009) Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol 247:1165–1171

    Article  CAS  PubMed  Google Scholar 

  29. Gross NE, Aizman A, Brucker A, Klancnik JM Jr, Yannuzzi LA (2005) Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 25:713–718

    Article  PubMed  Google Scholar 

  30. Chang YS, Kim JH, Yoo SJ, Lew YJ, Kim J (2016) Fellow-eye neovascularization in unilateral retinal angiomatous proliferation in a Korean population. Acta Ophthalmol 94:e49–e53

    Article  CAS  PubMed  Google Scholar 

  31. Kim JH, Chang YS, Kim JW, Kim CG, Lee DW, Kim HS (2018) Long-term visual changes in initially stronger fellow eyes in patients with unilateral type 3 neovascularization. Retina doi: https://doi.org/10.1097/IAE.0000000000002239

Download references

Funding

Kim’s Eye Hospital (Seoul, South Korea) provided financial support in the form of funding for English editing support. The sponsor had no role in the design or conduct of this research.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Kim’s Eye Hospital, Konyang University College of Medicine, #156 Youngdeungpo-dong 4ga, Youngdeungpo-gu, Seoul, 150-034, South Korea

    Jae Hui Kim, Jong Woo Kim, Chul Gu Kim & Dong Won Lee

  2. Department of Ophthalmology, Konyang University College of Medicine, Daejeon, South Korea

    Young Suk Chang

Authors
  1. Jae Hui Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Young Suk Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jong Woo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chul Gu Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dong Won Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jae Hui Kim.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by the Institutional Review Board of Kim’s Eye Hospital (Seoul, South Korea). This study was conducted in accordance with the tenets of the Declaration of Helsinki.

Informed consent

Informed consent was not obtained in this study. Identifying information about participants was not presented in this study.

Financial support

This study was supported by Kim’s Eye Hospital Research Center.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, J.H., Chang, Y.S., Kim, J.W. et al. Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment. Graefes Arch Clin Exp Ophthalmol 257, 1183–1189 (2019). https://doi.org/10.1007/s00417-019-04306-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-019-04306-1

Keywords

Search

Navigation